Intercept Pharmaceuticals Future Growth

Future criteria checks 4/6

Intercept Pharmaceuticals is forecast to grow earnings and revenue by 63.9% and 12.9% per annum respectively while EPS is expected to grow by 66.1% per annum.

Key information

63.9%

Earnings growth rate

66.1%

EPS growth rate

Biotechs earnings growth	0%
Revenue growth rate	12.9%
Future return on equity	n/a
Analyst coverage	Good
Last updated	07 Jun 2023

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BMV:ICPT * - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	451	115	-16	-135	12
12/31/2024	413	34	81	97	15
12/31/2023	328	-76	-51	-141	16
3/31/2023	295	-173	-59	-58	N/A
12/31/2022	286	-175	-27	-27	N/A
9/30/2022	277	-202	-18	-17	N/A
6/30/2022	266	-115	3	3	N/A
3/31/2022	263	-120	-7	-7	N/A
12/31/2021	261	-136	-41	-41	N/A
9/30/2021	275	-144	-65	-62	N/A
6/30/2021	288	-193	-110	-106	N/A
3/31/2021	297	-231	-130	-126	N/A
12/31/2020	234	-273	-176	-172	N/A
9/30/2020	301	-321	-217	-215	N/A
6/30/2020	283	-339	-222	-221	N/A
3/31/2020	272	-347	-253	-252	N/A
12/31/2019	252	-345	-238	-237	N/A
9/30/2019	234	-335	-230	-229	N/A
6/30/2019	219	-314	-235	-234	N/A
3/31/2019	196	-318	-236	-235	N/A
12/31/2018	180	-309	-241	-241	N/A
9/30/2018	164	-333	-265	-264	N/A
6/30/2018	159	-341	-271	-269	N/A
3/31/2018	146	-352	-283	-277	N/A
12/31/2017	131	-360	-276	-265	N/A
9/30/2017	107	-369	-290	-278	N/A
6/30/2017	71	-385	-343	-334	N/A
3/31/2017	46	-376	-357	-350	N/A
12/31/2016	25	-413	N/A	-342	N/A
9/30/2016	12	-381	N/A	-319	N/A
6/30/2016	7	-343	N/A	-240	N/A
3/31/2016	2	-314	N/A	-203	N/A
12/31/2015	3	-226	N/A	-163	N/A
9/30/2015	3	-173	N/A	-129	N/A
6/30/2015	3	-158	N/A	-120	N/A
3/31/2015	3	-77	N/A	-105	N/A
12/31/2014	2	-283	N/A	-88	N/A
9/30/2014	2	-261	N/A	-66	N/A
6/30/2014	2	-257	N/A	-49	N/A
3/31/2014	2	-304	N/A	-35	N/A
12/31/2013	2	-68	N/A	-28	N/A
9/30/2013	2	-86	N/A	-22	N/A
6/30/2013	2	-61	N/A	-19	N/A
3/31/2013	2	-53	N/A	-17	N/A
12/31/2012	2	-46	N/A	-16	N/A
9/30/2012	3	-20	N/A	-16	N/A
6/30/2012	3	-17	N/A	-14	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ICPT * is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (7.6%).

Earnings vs Market: ICPT * is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ICPT * is expected to become profitable in the next 3 years.

Revenue vs Market: ICPT *'s revenue (12.9% per year) is forecast to grow faster than the MX market (6.2% per year).

High Growth Revenue: ICPT *'s revenue (12.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ICPT *'s Return on Equity is forecast to be high in 3 years time

Intercept Pharmaceuticals Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Intercept Pharmaceuticals Provides Net Sales Guidance for the Full Year of 2023

Forecast breakeven date pushed back to 2025

Forecast breakeven date moved forward to 2022

Forecast breakeven date moved forward to 2022

Forecast breakeven date moved forward to 2022

Recent updates

Intercept Pharmaceuticals, Inc. Receives Complete Response Letter from FDA Addressing OCALIVA Supplemental New Drug Application (sNDA)

Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA

Intercept Announces Statement on FDA Advisory Committee Meeting

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals' Common Stock Ceased to be Traded on the NASDAQ Stock Market

Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT).

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Alfasigma S.p.A. entered into a definitive merger agreement to acquire Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT) for approximately $840 million.

Intercept Pharmaceuticals Provides Net Sales Guidance for the Full Year of 2023

Intercept Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Intercept Pharmaceuticals, Inc. Presents New Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage

Intercept Pharmaceuticals, Inc. Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Full year 2022 earnings released: US$5.17 loss per share (vs US$2.87 loss in FY 2021)

U.S. Food and Drug Administration Accepts Intercept Pharmaceuticals, Inc.'s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to Nash

Forecast breakeven date pushed back to 2025

Intercept Pharmaceuticals, Inc. Resubmits New Drug Application to U.S. Fda for Obeticholic Acid in Patients with Liver Fibrosis Due to NASH

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

Third quarter 2022 earnings released: US$3.04 loss per share (vs US$0.11 loss in 3Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid in Compensated Cirrhosis Due to Nash Did Not Meet Its Primary Endpoint

Intercept Pharmaceuticals, Inc. Announces Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology

Second quarter 2022 earnings released: US$0.68 loss per share (vs US$0.33 loss in 2Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022

Forecast breakeven date moved forward to 2022

Forecast breakeven date moved forward to 2022

Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)

Intercept Pharmaceuticals, Inc. Provides Update on Nash Regulatory Timeline

Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance

Forecast breakeven date moved forward to 2022

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies